Sökning: "mid-‐range ejection fraction"
Visar resultat 1 - 5 av 6 avhandlingar innehållade orden mid-‐range ejection fraction.
1. How to create and analyze a Heart Failure Registry with emphasis on Anemia and Quality of Life
Sammanfattning : Background and aimsHeart failure (HF) is a major cause of serious morbidity and death in the population and one of the leading medical causes of hospitalization among people older than 60 years. The aim of this thesis was to describe how to create and how to analyze a Heart Failure Registry with emphasis on Anemia and Quality of Life. LÄS MER
2. Heart failure : role of metabolic biomarkers, ejection fraction, and sex
Sammanfattning : Background: Heart failure (HF) is common and associated with impaired quality of life (QoL) and poor prognosis. There is a ternary classification of HF based on ejection fraction (EF): HF with preserved(HFpEF), mid-range EF(HFmrEF), and reduced EF(HFrEF). LÄS MER
3. The important role of left atrial function parameters in clinical practice
Sammanfattning : The aim of this thesis is to evaluate the role of left atrial function in clinical practice based on the following studies:1) Determining left atrial (LA) structure and myocardial function measurements that predict pulmonary capillary wedge pressure (PCWP).2) Identifying predictors of exercise capacity in patients with HFpEF and right ventricle (RV) dysfunction. LÄS MER
4. Renal dysfunction in heart failure : insights on prevalence and prognosis
Sammanfattning : Background: Kidney disease is common in heart failure (HF) and has been found to be associated with worse outcomes. The impact of different degrees of chronic kidney disease (CKD) in HF, as well as the link to, and impact of CKD in HF with reduced (HFrEF), the newly defined mid-range (HFmrEF) and preserved ejection fraction (HFpEF) have been uncertain. LÄS MER
5. Biomarkers for eligibility and surrogate endpoints in heart failure trials
Sammanfattning : Background: In heart failure (HF) with reduced ejection fraction (HFrEF), randomized controlled trials have provided effective treatments, but prognosis still remains poor. HF with mid-range EF (HFmrEF) has no evidencebased therapy and represents a newly characterized and relevant population for future trials. LÄS MER